癌症抗血管生成治疗的现状与展望。
Current status and future prospects for anti-angiogenic therapies in cancer.
机构信息
University of Sheffield, School of Medicine and Biomedical Sciences, Microcirculation Research Group, Academic Unit of Surgical Oncology, Beech Hill Road, Sheffield, South Yorkshire, S10 2RX, UK +44 (0)114 226 5852 ; +44 (0)114 271 3314 ;
出版信息
Expert Opin Drug Discov. 2009 Sep;4(9):961-79. doi: 10.1517/17460440903196737.
BACKGROUND
Angiogenesis is essential for tumour growth and development and since the pioneering work of Judah Folkman several anti-angiogenic strategies have now been successfully employed.
OBJECTIVE
This article aims to present a detailed review of current knowledge of the main pathways involved in angiogenesis, the strategies employed for inhibition and the current status of angiogenesis inhibitors in therapeutic use.
METHODS
A systematic review of the literature was undertaken including angiogenesis in cancer and angiogenesis inhibitors in pre-clinical and clinical trials.
CONCLUSION
While angiogenic inhibitors are now in clinical use, their limited benefits mean we must urgently develop strategies to improve the efficacy of this approach.
背景
血管生成对于肿瘤的生长和发展至关重要，自 Judah Folkman 的开创性工作以来，目前已经成功采用了几种抗血管生成策略。
目的
本文旨在详细综述血管生成中涉及的主要途径、用于抑制的策略以及治疗中使用的血管生成抑制剂的现状。
方法
对包括癌症中的血管生成和临床前及临床试验中的血管生成抑制剂的文献进行系统综述。
结论
虽然血管生成抑制剂已在临床应用，但它们的有限疗效意味着我们必须紧急开发策略来提高这种方法的疗效。
Zotero 插件